1. INTRODUCTION {#s0005}
===============

Patients with end-stage liver disease undergoing liver transplantation (LT) often suffer from severe coagulopathy, thrombocytopenia, and platelet dysfunction which place them at increased risk for hemorrhagic complications \[[@bb0005],[@bb0010]\]. This clinical dilemma is compounded by the modern understanding that patients with liver disease exhibit an imbalance of both procoagulant and anticoagulant clotting factors \[[@bb0015]\]. The resulting fragile equilibrium within the coagulation cascade places patients at risk for both bleeding and thrombotic events wherein minor physiological insults can incite hemostatic pathology. Therefore, it is necessary to understand the dynamic coagulation states of these patients perioperatively as they undergo the major physiological stress associated with LT.

Several studies have demonstrated that conventional coagulation tests including prothrombin time, activated partial thromboplastin time, and international normalized ratio (INR) fail to accurately predict bleeding risk in cirrhotic patients \[[@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]\]. In these patients, conventional coagulation tests typically produce a falsely elevated result because they only capture the decreased prothrombotic clotting factors and do not necessarily represent the patient\'s complex hemostatic state \[[@bb0005],[@bb0010],[@bb0045]\]. Additionally, conventional tests provide a single numerical value which correlates to the time for initial clot formation and lack the ability to describe the dynamic kinetics of the in vivo clotting cascade. As a result, blood product utilization and transfusion requirements during LT remain highly variable and difficult to predict \[[@bb0050]\].

In contrast, thrombelastography (TEG) is a point-of-care hemostasis assessment tool that offers a more comprehensive evaluation of a patient\'s coagulation status through direct measurement of the strength of clot formation, stability, and lysis \[[@bb0020],[@bb0025],[@bb0050],[@bb0055]\]. The hemodilution, acidosis, metabolic byproducts, and hypothermia that occur during LT, particularly during the anhepatic and neohepatic/reperfusion phases, can precipitate coagulopathy \[[@bb0040]\]. TEG may inform clinicians about the overall coagulation status while factoring in complex hemostatic changes that are occurring at the patient level. Although TEG use has grown within the field of liver transplantation, peri- and intraoperative TEG profiles and the implications of TEG use remain largely unknown. Our aim was to assess the prevalence of TEG-based coagulopathy in patients undergoing LT and determine the significance of a preoperative hypocoagulable state on various intraoperative and perioperative outcomes. We hypothesized that patients would demonstrate major shifts in coagulation profiles during LT and that hypocoagulable patients would have greater blood product transfusion requirements during and after LT.

2. METHODS {#s0010}
==========

2.1. Study population {#s0015}
---------------------

This study was approved by the University of Cincinnati Institutional Review Board. A retrospective review of a prospectively-maintained LT database was performed to identify all patients undergoing LT between January 2013 to May 2017 at a single academic institution (*n* = 380). Although our institution does not currently have a formalized TEG utilization protocol for liver transplantation, nearly all patients received a preoperative TEG to establish a baseline for comparison to a postoperative TEG obtained in the intensive care unit (ICU). With increasing TEG use among many surgical specialties, it became increasingly used by our surgical and anesthesia teams intraoperatively to monitor changes in coagulation status along with traditional laboratory assessments. The decision to transfuse was multifactorial based on the clinical situation, judgment of the surgeon and anesthesiologist, and assessment of hemodynamic and physiologic laboratory values. If transfusion was deemed necessary and TEG was available, this coagulation testing guided selection of blood products administered. However, there are no absolute numerical cutoffs for which we transfuse specific blood products empirically based on the TEG measurements.

Available TEG data were reviewed, and only patients with preoperative TEG data were included in this study (*n* = 364). Subgroup analyses were performed to (1) compare TEG profiles before and after LT for patients who had both preoperative and postoperative data (*n* = 243) and (2) to evaluate shifts in coagulation profiles during each of the phases of LT (preoperative, anhepatic, neohepatic, postoperative) for those patients with TEG values at each phase (*n* = 110). Differences between groups were analyzed for demographic data, severity and etiology of end-stage liver disease, donor characteristics, and intraoperative and perioperative transfusion of packed red blood cells (pRBCs), fresh frozen plasma (FFP), platelets, and cryoprecipitate. LT recipient outcomes including durations of intensive care unit (ICU) and hospital stay, and mortality were assessed.

2.2. Thrombelastography classification {#s0020}
--------------------------------------

TEG measurements collected for analysis included reaction (*R*) time, coagulation (*k*) time, *α* angle, and maximum amplitude (MA) ([Fig. 1](#f0005){ref-type="fig"}). These values were collected at 4 phases of LT: preoperative, anhepatic, neohepatic, and the initial postoperative phase of LT. The preoperative and postoperative TEG readings were collected within 4 hours of the case\'s start and end times, respectively. Using methodology described by Kaufmann et al, coagulation profiles were categorized as hypocoagulable, hypercoagulable, or normal based on composite rapid TEG profiles of *R* time, *k* time, *α* angle, and MA \[[@bb0060]\]. Hypocoagulable was defined as having 2 of the following: *R* time \> 44 seconds or *k* time \> 138 seconds, *α* angle \< 64°, and MA \< 52 mm. Conversely, hypercoagulable was defined as having 2 of the following: *R* time \< 22 seconds or *k* time \< 138 seconds, *α* angle \> 80°, and MA \> 71 mm. The reference ranges (*R* time 22--44 seconds; *k* time 34--138 seconds; *α* angle 64°--80°; MA 52--71 mm) based on laboratory standards and daily quality control samples were used to determine numerical cutoffs of coagulation status.Fig. 1Depiction of a thrombelastography tracing. The x-axis is time and the y-axis is clot strength. *R* represents time to initiation of clot formation. *k* and related *α* angle represent the rate of clot strengthening. MA represents maximal strength of the formed clot.Fig. 1

2.3. Statistical analysis {#s0025}
-------------------------

All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC). Given the limited number of hypercoagulable patients, a statistical analysis was performed comparing patients with data for all 4 phases of LT with preoperatively normal (*n* = 52) and hypercoagulable (*n* = 4) TEGs. This demonstrated that these patients were not significantly different in demographics or outcomes (data not shown). Therefore, these patients were grouped together as nonhypocoaguable and compared to hypocoaguable patients for this analysis. Continuous data are reported as median and interquartile range (IQR) and compared using the Wilcoxon rank-sum and Kruskal-Wallis tests. Categorical data are reported as total (*n*) and percentage (*%*) and compared using the *χ*^2^ test (or Fisher exact tests for rare occurrences). Multivariate logistic regression analyses were performed to identify predictors of transfusion requirements within 24 hours of LT. Covariates included preoperative factors of age, sex, ethnicity, body mass index (BMI), coagulation status, Model for End-Stage Liver Disease (MELD) score, preoperative dialysis dependency, admitted at time of LT, and total ischemia time. Statistical significance was set at *P* \< .05.

3. RESULTS {#s0030}
==========

3.1. Study cohort and TEG profiles {#s0035}
----------------------------------

The study cohort consisted of 364 patients with complete TEG data who underwent LT during the study period ([Table 1](#t0005){ref-type="table"}). Among all patients, 170 (46.7%) presented for LT in a hypocoagulable state. Among those who had both a pre- and post-LT TEG, 39.9% (*n* = 97) finished the operation in a different category of coagulation from which they started ([Table 2](#t0010){ref-type="table"}). A total of 44.6% (*n* = 54) were hypocoagulable to begin the LT but returned to the ICU nonhypocoagulable, whereas 35.3% (*n* = 43) were nonhypocoagulable and arrived to the ICU hypocoagulable. Next, a subgroup analysis of patients with complete TEG data for all phases of LT (*n* = 110) was performed. During LT, there was a notable increase in hypocoagulability as the operation progressed ([Table 3](#t0015){ref-type="table"}). Although 49.1% (*n* = 54) of patients started the operation in a hypocoagulable state, this number increased to 66.4% (*n* = 73) in the anhepatic phase and 75.5% (*n* = 83) in the neohepatic phase. This trend toward becoming hypocoagulable was largely resolved by the end of the operation, as 45.5% (*n* = 50) of patients demonstrated a postoperative hypocoagulable TEG.Table 1Cohort demographicsTable 1Liver transplants (n = 364)\
N (%)/Median (IQR)Age, y58(51--63)Sex, male231(63.5%)BMI, kg/m^2^30(25--34)MELD (allocation)23(21--28)Ethnicity White327(89.8%) African American33(9.1%) Other4(1.1%)Etiology ETOH77(21.2%) NASH83(22.8%) HBV/HCV110(30.2%) Other94(25.8%)Dialysis prior to LT58(15.9%)LT type Whole331(91.2%) SLK32(8.8%)Donor age, y38(27--52)Donor BMI, kg/m^2^28(24--32)DCD24(6.6%)Total ischemia time, min352(290--445)Biliary complications65(17.86%)Hepatic artery thrombosis10(2.7%)Primary nonfunction3(0.8%)Acute cellular rejection12(3.3%)Length of stay, d8(6--16)30-d readmission101(37.6%)30-d mortality71.9%1-y mortality154.1%Preoperative TEG *R* time, s50(40--60) *k* time, s120(76.3--180) MA, mm52.1(45--59.1) *α* angle, °72.7(66.4--77.1)Preoperative coagulation status Hypocoagulable170(46.7%) Nonhypocoagulable194(53.3%)[^1]Table 2Changes in coagulation profiles between preoperative versus postoperativeTable 2Coagulation profilePreoperative hypocoagulablePreoperative nonhypocoagulable**N(%)N(%)**Postoperative hypocoagulable67(55.4%)43(35.3%)Postoperative nonhypocoagulable54(44.6%)79(64.8%)[^2]Table 3Distribution of coagulation profiles by phase of liver transplantationTable 3\
LT phaseHypocoagulableNonhypocoagulable**N(%)N(%)**Preoperative54(49.1%)56(50.9%)Anhepatic73(66.4%)37(33.6%)Neohepatic83(75.5%)27(24.5%)Postoperative50(45.5%)60(54.5%)[^3]

3.2. Comparison of patients by preoperative coagulation state {#s0040}
-------------------------------------------------------------

Patients who were hypocoagulable by TEG assessment at the start of LT were compared to those who were nonhypocoagulable ([Table 4](#t0020){ref-type="table"}). There were no significant differences found between the groups with regard to recipient characteristics including sex, ethnicity, BMI, or etiology of liver disease (all *P* \> .05). Nonhypocoagulable patients were slightly older than hypocoagulable patients (59 vs 57, *P* = .04). Hypocoagulable patients had higher median MELD (26 vs 22, *P* \< .01). There were no differences in the donor characteristics between the groups (all *P* \> .05).Table 4Demographics for patients undergoing LT by preoperative coagulation stateTable 4HypocoagulableNonhypocoagulable\
*P*N (%)/Median (IQR)N (%)/Median (IQR)Age, y57(49--62.3)59(52--64).036[⁎](#tf0005){ref-type="table-fn"}Sex, male104(61.2%)127(65.5%).397BMI, kg/m^2^30(26--34)30(25--33).248MELD (allocation)26(22--34)22(19--27)\< .001[⁎](#tf0005){ref-type="table-fn"}MELD (allocation) over 3532(18.8%)8(4.1%)\< .001[⁎](#tf0005){ref-type="table-fn"}Ethnicity.835 White151(88.2%)176(90.7%) African American17(10.0%)16(8.3%) Other2(1.2%)2(1.0%)ABO blood type.750 A69(40.6%)70(36.1%) B17(10.0%)25(12.9%) AB10(5.9%)11(5.7%) O74(43.5%)88(45.4%)Etiology.295 ETOH37(21.8%)40(20.6%) NASH34(20.0%)49(25.8%) HCV/HBV55(32.4%)55(28.4%) Other44(25.9%)50(25.8%)Diabetes39(22.9%)58(29.9%).134LT type.064 Whole160(94.1%)171(88.6%) SLK10(5.9%)22(11.4%)Hypertension67(39.4%)97(50.0%).043[⁎](#tf0005){ref-type="table-fn"}HCC30(17.7%)57(29.4%).009[⁎](#tf0005){ref-type="table-fn"}Dialysis prior to LT38(22.4%)20(10.3%).002[⁎](#tf0005){ref-type="table-fn"}Admitted at time of LT80(47.1%)29(15.0%)\< .001[⁎](#tf0005){ref-type="table-fn"}PVT17(10.1%)17(8.7%).672SBP11(6.5%)8(4.1%).351Donor characteristics Donor age36(27--50)40(28--54).116 DCD11(6.5%)13(6.7%).930Preoperative INR2.1(1.7--2.6)1.4(1.2--1.7)\< .001[⁎](#tf0005){ref-type="table-fn"}Warm ischemia time34(30--40)34(30--41).581Total OR time340(294--405)336(293--400).749Preoperative TEG *R* time, s55(45--70)40(35--50)\< .001[⁎](#tf0005){ref-type="table-fn"} *k* time, sec185(155--226)80(60--105)\< .001[⁎](#tf0005){ref-type="table-fn"} MA, mm44.4(39.6--47.6)58.4(54.8--62.8)\< .001[⁎](#tf0005){ref-type="table-fn"} *α* angle, °65.8(60.8--69.6)76.6(74.1--78.6)\< .001[⁎](#tf0005){ref-type="table-fn"}[^4][^5]

Outcomes between these 2 groups were then evaluated ([Table 5](#t0025){ref-type="table"}). Hypocoagulable patients had higher transfusion requirements, requiring more pRBCs (7 vs 4 U, *P* \< .001), FFP (14 vs 8 U, *P* \< .001), cryoprecipitate (2 vs 1 U, *P* \< .01), platelets (3 vs 2 U, *P* \< .01), and cell saver (3 vs 2 L, *P* \< .01) during the operation compared to those with nonhypocoagulable preoperative TEGs. In the first 24 hours postoperatively, a larger proportion of hypocoagulable patients were administered cryoprecipitate (25.3% vs 14.4%, *P* \< .01) and platelets (37.1% vs 19.6%, *P* \< .01), but postoperative transfusion of pRBCs (44.1% vs 35.1%, *P* = .08) and FFP (45.3% vs 36.6%, *P* = .09 were similar. On multivariate analysis, preoperative coagulation status was not independently associated with 24-hour transfusion requirements (data not shown).Table 5Outcomes for patients undergoing LT by preoperative coagulation stateTable 5Start hypocoagulableStart nonhypocoagulable\
*P*N (%) / Median (IQR)N (%) / Median (IQR)Transfusion requirements pRBCs7(4--10)4(2--9)\< .001[⁎](#tf0010){ref-type="table-fn"} FFP14(9-24)8(3.75--14)\< .001[⁎](#tf0010){ref-type="table-fn"} Cryoprecipitate2(1--5)1(0--2)\< .001[⁎](#tf0010){ref-type="table-fn"} Platelets3(2--5)2(0--3)\< .001[⁎](#tf0010){ref-type="table-fn"} Cell saver3(1.75--5.1)2(1--3.33)\< .001[⁎](#tf0010){ref-type="table-fn"} Estimated blood loss, L8(5--13.9)5.5(3--9.15)\< .001[⁎](#tf0010){ref-type="table-fn"} 24-h pRBC75(44.1%)68(35.1%).077 24-h FFP77(45.3%)71(36.6%).092 24-h cryoprecipitate43(25.3%)28(14.4%).009[⁎](#tf0010){ref-type="table-fn"} 24-h platelets63(37.1%)38(19.6%)\< .001[⁎](#tf0010){ref-type="table-fn"}Surgical outcomes Reoperation61(36.1%)65(33.9%).656 Unplanned reoperation36(21.2%)39(20.3%).840 Open abdomen34(20.1%)30(15.6%).265Allograft outcomes HAT3(1.76%)7(3.65%).276 Biliary complications28(16.5%)37(19.1%).518 DGF10(5.92%)13(6.77%).740Hospital course Vent \> 24 h61(36.1%)49(25.5%).029 ICU LOS3(2--5)3(2--4).113 ICU readmission21(12.4%)20(10.3%).538 Hospital LOS9(6--16)8(6--14).121 30-d readmission50(38.2%)51(37.0%).838 30-d mortality4(2.4%)3(1.6%).710 1-y mortality9(5.3%)6(3.1%).306[^6][^7]

Despite differences in blood product utilization, no differences between groups for postoperative outcomes were detected including number of reoperations (total and unplanned), number of patients requiring temporary abdominal closure, length of stay, readmission, or mortality.

4. DISCUSSION {#s0045}
=============

Herein, we studied TEG-based coagulation profiles of patients undergoing LT and found that, preoperatively, half of patients were hypocoagulable and half were nonhypocoagulable, with very few patients meeting criteria for hypercoagulable. Moreover, coagulation status was found to be dynamic, with 40% of patients finishing the operation in a different coagulation category than which they started. We identified that hypocoagulability increased during progression from the preoperative to the anhepatic and neohepatic phases of LT but normalized in the early postoperative setting. Compared to nonhypocoagulable patients, patients who were hypocoagulable preoperatively received increased perioperative administration of plasma, cryoprecipitate, platelets, and autologously transfused blood during LT, as well as increased cryoprecipitate and platelets in the first 24 hours after LT. Nonetheless, postoperative outcomes were similar between the groups.

TEG is a point-of-care hemostasis assay which can assess the mechanical properties of clot formation, progression, stability, as well as the resulting dynamics of the coagulation cascade \[[@bb0005],[@bb0010]\]. Although TEG has proven itself important in other surgical fields, data on the characterization of TEG-based coagulopathy throughout LT are not well described. This study serves as the first to our knowledge to characterize specific TEG profiles during the phases of LT. We found a 26.4% increase in the prevalence of hypocoagulability from the preoperative to anhepatic state. However, this transition to a hypocoagulable state subsided following LT upon arriving to the ICU with the initiation of allograft function.

During LT, a complex array of physiological factors incites alterations of a patient\'s coagulation and destabilizes the prothrombotic and antithrombotic equilibrium \[[@bb0065]\]. These stressors include hemorrhage, dilutional coagulopathy, alternations in hepatic synthetic function, and changes in metabolic release and clearance of coagulation factors \[[@bb0050],[@bb0065],[@bb0070]\]. Initially, there is possibility for bleeding during hepatic dissection and recipient hepatectomy which can be significantly exacerbated by portal hypertension \[[@bb0050]\]. Next, during the anhepatic phase, there is a loss of synthetic function with decreased factor production and decreased tissue plasminogen activator (tPA) clearance. These changes shift the hemostatic balance toward hypocoagulation and hyperfibrinolysis \[[@bb0050]\]. Subsequently, the neohepatic phase represents a period of hemostatic vulnerability with potential for clinically relevant coagulopathies. Reperfusion may cause a heparin-like effect identifiable on TEG with a prolonged *R* and *k* time and decreased MA \[[@bb0075]\]. As the liver allograft is reperfused, an increase in tPA production during the neohepatic phase augments hyperfibrinolysis. Our work supports these pathophysiologic processes because we found an increase in prevalence of hypocoagulability throughout LT.

As TEG becomes more commonplace in surgery, including LT, it is logical then to study the impact TEG use has on transfusion requirements. Our data showing increased blood product administration in hypocoagulable patients suggest utility in correlating preoperative TEG with transfusion requirements. These findings are particularly important in the context of the increasing awareness of the negative ramifications of massive transfusions. There is no consensus on TEG-based transfusion guidelines in LT, and there is a paucity of data about the benefits of adopting such guidelines to further reduce the administration of blood products \[[@bb0050]\]. Existing work in LT is limited. Pietri et al determined significantly decreased plasma and platelet administration in LT when transfusing based on TEG compared to protocols defined by INR and serum platelet count \[[@bb0005]\]. Similarly, Wang et al identified that TEG-based transfusion in LT successfully reduced the quantity of plasma administered compared to the protocols based on prothrombin time and INR \[[@bb0055]\].

As may be expected, preoperative hypocoagulable TEG is associated with patients who have more advanced disease and significant hepatic pathology. We found that hypocoagulable patients had increased MELD scores and a higher proportion were admitted at the time of LT, most commonly to the medical intensive care unit for an exacerbation or decompensation of their underlying disease. In contrast, hepatocellular carcinoma was more common in nonhypocoagulable patients. This may be due to these patients having less advanced end-organ failure, as the liver transplant allocation system provides allocation points for patients with hepatocellular carcinoma.

In light of these patient differences, which ultimately serve as risk factors for hypercoagulation and is thus captured by their TEG profile, we noted that hypocoagulable patients had higher estimated blood loss and increased intraoperative and postoperative blood product administration. Although preoperative hypocoagulable TEG readings were associated with increased transfusion requirements, we did not demonstrate a difference in postoperative outcomes or graft function between groups. Moreover, TEG-defined hypocoagulable state was not an independent predictor of transfusion requirements in the first 24 hours postoperatively on multivariate analysis. This is likely due to the nature of these outcomes, such as length of stay and reoperation rate, which depend on multiple factors, of which blood loss and resuscitation play a part. Elevated INR has been shown to be correlated with decreased survival, but the relationship between TEG readings and the impact on long-term graft and patient outcomes has not been previously demonstrated \[[@bb0005]\]. The similarity in postoperative outcomes between groups may be attributed to the appropriate administration of intraoperative transfusions and resulting stabilization of coagulopathy once in the postoperative setting. Despite similar outcomes, the importance of our findings relates to our demonstrating the utility in using TEG for assessment of coagulation status in the hemodynamically complex OLT. Future work to understand possible predictive abilities of TEG will prove valuable.

This study has several limitations. First, the retrospective nature of the study imparts certain biases inherent to such study design. Second, regulation of fibrinolysis has been shown to be an integral component of maintaining physiologic coagulation status; however, this variable was not included in our study\'s definition of coagulability \[[@bb0080]\]. Third, we used previously described cutoffs for TEG values to stratify patients\' coagulation status. However, well-defined TEG values among LT patients are unknown, and shifts in cutoff values could alter definitions of coagulation status. Fourth, we cannot fully account to what degree TEG itself functioned as an intraoperative evaluative tool that influenced blood product administration. The decision to administer blood products intraoperatively was determined by the anesthesiologist\'s and surgeon\'s assessment in the operating room of subjective coagulation status in conjunction with the TEG, although no formal protocols were used.

In conclusion, patients undergoing LT suffer from liver disease with imbalances in coagulation factors leading to a delicate state of fluctuation between hypo- and hypercoagulability. Using TEG-based assessment of coagulation status, we identified that a majority of patients underwent LT in a hypocoagulable state with a greater prevalence of hypocoagulability during the anhepatic and neohepatic phases, which normalizes postoperatively. When available, TEG assessment should be performed for patients undergoing LT to optimize surgical planning and improve resource utilization during LT. Moving forward, future work is required to provide insight to the additional predictive potential of TEG, as well as its impact on long-term outcomes.
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[^1]: *DCD*, donation after cardiac death; *ETOH*, alcoholic cirrhosis; *HBV*, hepatitis B virus; *HCV*, hepatitis C virus; *NASH*, nonalcoholic steatohepatitis; *SLK*, simultaneous liver-kidney.

[^2]: n = 243 for cohort with complete pre- and posteropative TEG data.

[^3]: n = 110 for cohort with complete TEG data at all phases of LT.

[^4]: *HCC*, hepatocellular carcinoma; *OR*, operating room; *PVT*, portal vein thrombosis; *SBP*, spontaneous bacterial peritonitis.

[^5]: *P* \< .05.

[^6]: *DGF*, delayed graft function; *HAT*, hepatic artery thrombosis; *LOS*, length of stay.

[^7]: *P* \< .05.
